Ginkgo Bioworks Holdings (DNA) Non-Current Deffered Revenue (2020 - 2026)

Ginkgo Bioworks Holdings has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $77.9 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 3.09% year-over-year to $77.9 million; the trailing twelve-month figure through Mar 2026 stood at $77.9 million (down 3.09% YoY), and the FY2025 full-year result was $75.2 million, down 23.89% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $77.9 million, up from $75.2 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $179.9 million in Q2 2023, with the low at $20.2 million in Q2 2022.
• Historically, Non-Current Deffered Revenue has averaged $123.7 million across 5 years, with a median of $150.6 million in 2022.
• The largest YoY upside for Non-Current Deffered Revenue was 832.29% in 2022 against a maximum downside of 66.52% in 2022.
• Ginkgo Bioworks Holdings' Non-Current Deffered Revenue stood at $174.8 million in 2022, then fell by 9.56% to $158.1 million in 2023, then sank by 37.5% to $98.8 million in 2024, then declined by 23.89% to $75.2 million in 2025, then advanced by 3.61% to $77.9 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $77.9 million (Q1 2026), $75.2 million (Q4 2025), and $74.1 million (Q3 2025), per Business Quant data.